DOCSLIB.ORG

Evidence-Based Clinical Practice Guidelines for Peptic Ulcer Disease 2020

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evidence-Based Clinical Practice Guidelines for Peptic Ulcer Disease 2020 J Gastroenterol https://doi.org/10.1007/s00535-021-01769-0 REVIEW Evidence-based clinical practice guidelines for peptic ulcer disease 2020 1,2 2 2 2 Tomoari Kamada • Kiichi Satoh • Toshiyuki Itoh • Masanori Ito • 2 2 2 2 Junichi Iwamoto • Tadayoshi Okimoto • Takeshi Kanno • Mitsushige Sugimoto • 2 2 2 2 Toshimi Chiba • Sachiyo Nomura • Mitsuyo Mieda • Hideyuki Hiraishi • 2 2 2 2 Junji Yoshino • Atsushi Takagi • Sumio Watanabe • Kazuhiko Koike Received: 7 October 2020 / Accepted: 3 February 2021 Ó The Author(s) 2021 Abstract The Japanese Society of Gastroenterology second-line therapy. Patients who do not use NSAIDs and (JSGE) revised the third edition of evidence-based clinical are H. pylori negative are considered to have idiopathic practice guidelines for peptic ulcer disease in 2020 and peptic ulcers. Algorithms for the prevention of NSAID- created an English version. The revised guidelines consist and low-dose aspirin (LDA)-related ulcers are presented in of nine items: epidemiology, hemorrhagic gastric and this guideline. These algorithms differ based on the con- duodenal ulcers, Helicobacter pylori (H. pylori) eradica- comitant use of LDA or NSAIDs and ulcer history or tion therapy, non-eradication therapy, drug-induced ulcers, hemorrhagic ulcer history. In patients with a history of non-H. pylori, and nonsteroidal anti-inflammatory drug ulcers receiving NSAID therapy, PPIs with or without (NSAID) ulcers, remnant gastric ulcers, surgical treatment, celecoxib are recommended and the administration of VPZ and conservative therapy for perforation and stenosis. is suggested for the prevention of ulcer recurrence. In Therapeutic algorithms for the treatment of peptic ulcers patients with a history of ulcers receiving LDA therapy, differ based on ulcer complications. In patients with PPIs or VPZ are recommended and the administration of a NSAID-induced ulcers, NSAIDs are discontinued and anti- histamine 2-receptor antagonist is suggested for the pre- ulcer therapy is administered. If NSAIDs cannot be dis- vention of ulcer recurrence. continued, the ulcer is treated with proton pump inhibitors (PPIs). Vonoprazan (VPZ) with antibiotics is recom- Keywords Peptic ulcer Á Helicobacter pylori eradication Á mended as the first-line treatment for H. pylori eradication, Nonsteroidal anti-inflammatory drug Á Low-dose aspirin Á and PPIs or VPZ with antibiotics is recommended as a Idiopathic ulcer The members of the Guidelines Committee are listed in the Appendix. The original version of this article appeared in Japanese as ‘‘Shokasei Introduction Kaiyo Sinryo Guideline 2020’’ from the Japanese Society of Gastroenterology (JSGE), published by Nankodo, Tokyo, in 2020. In 2009, the Japanese Society of Gastroenterology (JSGE) Please see the article on the standards, methods, and process of developed evidence-based clinical practice guidelines for developing the guidelines. peptic ulcer disease. The guidelines were revised in 2015 and again in 2020. Of the 90 clinical questions (CQs) & Tomoari Kamada included in the previous guidelines, those with a clear [email protected] conclusion were considered background questions (BQs) 1 Department of Health Care Medicine, Kawasaki Medical and those requiring future research were considered future School General Medical Center, 2-6-1, Nakasange, Kita-ku, research questions (FRQs) in this revised guideline. Thus, Okayama 700-8505, Japan the revised guidelines consist of nine items (28 CQs and 2 Guidelines Committee for Creating and Evaluating the one FRQ), including, for the first time, epidemiology and ‘‘Evidence-Based Clinical Practice Guidelines for Peptic remnant gastric ulcer. Both epidemiology and conservative Ulcer,’’ the Japanese Society of Gastroenterology (JSGE), 6F Shimbashi i-MARK Bldg., 2-6-2 Shimbashi, Minato-ku, therapy for perforation and stenosis included only BQ. The Tokyo 105-0004, Japan prevention of hemorrhagic peptic ulcers in patients taking 123 http://guide.medlive.cn/ J Gastroenterol antithrombotic drugs and the treatment of ischemic duo- • Recommended that aspirin be continued for conditions denal ulcers have been added as a CQ and FRQ, at high risk for thromboembolic events. respectively. Recommendation: strong, 100% agreed, evidence level A literature search of Medline and the Cochrane Library B. was performed for data regarding the CQs published • Suggested to change antiplatelet agents to aspirin in between 1983 and October 2018, and the Igaku Chuo patients with conditions with a high risk of throm- Zasshi databases were searched for data published between boembolic events. 1983 and December 2018. The guidelines were developed Recommendation: weak, 100% agreed, evidence level using the Grading of Recommendations Assessment, D. Development and Evaluation (GRADE) system [1]. The • Suggested to suspend antiplatelet agents, except for in quality of evidence was graded as A (high), B (moderate), patients at high risk for thromboembolic events. C (low), and D (very low). Recommendation strength was Recommendation: weak, 100% agreed, evidence level indicated as either a ‘‘strong recommendation’’ or a ‘‘weak D. recommendation’’ The systematic review (SR) team con- • Recommended to suspend warfarin, if necessary, in ducted meta-analysis (MA) and decided the total strength endoscopic hemostasis patients. If warfarin is discon- of the evidence from A to D. The consensus was previously tinued, we suggest heparin or resuming warfarin as defined as 70% or more votes in agreement. soon as hemostasis is established. In Japan, incidence of cerebral infarction and myocar- Recommendation: strong, 100% agreed, evidence level dial infarction are increasing, and many patients undergo C. antithrombotic therapy including dual antiplatelet therapy • Suggested to resume DOACs early (within 1–2 days) (DAPT). In endoscopic clinical practice, focus has shifted after confirming endoscopic hemostasis. from the risk of gastrointestinal (GI) bleeding to throm- Recommendation: weak, 100% agreed, evidence level boembolism associated with the withdrawal of antithrom- D. botic therapy [2, 3]. In addition, for nearly 50 years, the • In patients receiving both antiplatelet agents and only oral anticoagulants were vitamin K antagonists warfarin, suggested to change antiplatelet agents to (warfarin); however, four non-vitamin K antagonist direct aspirin or cilostazol. Continue warfarin under a suit- oral anticoagulants (DOACs) are currently available. The able prothrombin time-international normalized ratio hemorrhagic gastric and duodenal ulcer section of the (PT-INR) or to change warfarin to heparin. revised guidelines emphasizes methods for the discontin- Recommendation: weak, 100% agreed, evidence level uation of antithrombotic therapy including DOACs and for D. the prevention of hemorrhagic ulcers in patients taking • In patients receiving dual antiplatelet agents, recom- anticoagulant and antiplatelet drugs, such as DAPT. mended that aspirin alone should be continued. Vonoprazan (VPZ) provides potent and long-lasting Recommendation: strong, 100% agreed, evidence level inhibition of gastric acid secretion, and its efficacy is, D. therefore, expected to be superior to that of proton pump Comment: The risk of re-bleeding due to continuing inhibitors (PPIs). Recent reports have shown that triple anticoagulant and/or antiplatelet agents and the risk of therapy including VPZ is as effective as first-line and thromboembolism associated with their withdrawal second-line therapies for the eradication of Helicobacter should be considered. One randomized controlled trial pylori [4]. Several reports have indicated that VPZ effec- (RCT) [8] reported significantly lower mortality in the tively heals peptic ulcers [5] and prevents the recurrence of continuing LDA group compared with the group that nonsteroidal anti-inflammatory drugs (NSAIDs) [6] and did not. However, clinical evidence is currently lacking low-dose aspirin (LDA)-related ulcers [7]. This revised to support the management of patients who receive version also emphasizes the clinical results of VPZ. antiplatelet agents excluding aspirin, warfarin, and DOACs with peptic ulcer bleeding (PUB). We consid- ered that these recommendations are based on expert Hemorrhagic gastric and duodenal ulcers opinions of the guidelines of Japan Gastroenterological Endoscopy, Asia–Pacific working group and European Non-endoscopic hemostatic therapy Society of Gastroenterological Endoscopy. It is neces- sary to collaborate closely with gastroenterologists and CQ-1 cardiologists as patients at high risk of thromboem- bolism with PUB could be unstable. Treatment of with patients with hemorrhagic peptic ulcers if they prescribed anticoagulants and/or antiplatelet agents? 123 http://guide.medlive.cn/ J Gastroenterol CQ-2 Prevention of hemorrhagic peptic ulcer Is interventional radiology (IVR) effective in patients CQ-4 undergoing refractory endoscopic treatment for hemor- rhagic peptic ulcers? What drugs are recommended for the prevention of hem- orrhagic ulcers in antithrombotic users? • In patients undergoing refractory endoscopic treatment for hemorrhagic peptic ulcers, interventional radiology • In DAPT, we recommend the combined use of PPIs to (IVR) is suggested due to its safety and effectiveness. prevent upper gastrointestinal bleeding (UGIB). Recommendation: weak, 100% agreed, evidence level Recommendation: strong, 100% agreed, evidence level C. A. Comment: The effectiveness of IVR with transcatheter • If taking warfarin, we suggest using PPIs to prevent arterial embolization
Load more

Recommended publications
  • Research Article the Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries
    Hindawi Gastroenterology Research and Practice Volume 2019, Article ID 6532876, 7 pages https://doi.org/10.1155/2019/6532876 Research Article The Protective Effect of Teprenone on Aspirin-Related Gastric Mucosal Injuries Jing Zhao ,1,2 Yihong Fan ,1,2 Wu Ye ,1 Wen Feng ,1 Yue Hu ,1,2 Lijun Cai ,1,2 and Bin Lu 1,2 1Department of Gastroenterology, First Affiliated Hospital of Zhejiang Chinese Medical University, 54 Youdian Road, Hangzhou 310006, China 2Key Laboratory of Digestive Pathophysiology of Zhejiang Province, First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China Correspondence should be addressed to Bin Lu; [email protected] Received 16 July 2018; Accepted 28 November 2018; Published 18 June 2019 Academic Editor: Haruhiko Sugimura Copyright © 2019 Jing Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Objective. Aspirin usage is associated with increased risk of gastrointestinal bleeding. The present study explored the potential of teprenone, an antiulcerative, in preventing aspirin-related gastric mucosal injuries. Methods. 280 patients with coronary diseases, naïve to aspirin medication, were admitted between 2011 and 2013 at the First Affiliated Hospital of Zhejiang Chinese Medical University and randomized into two groups (n = 140). The aspirin group received aspirin enteric-coated tablets 100 mg/day, while the aspirin+teprenone group received teprenone 50 mg 3 times/day along with aspirin. The patients were recorded for gastrointestinal symptoms and gastric mucosal injuries during a follow-up period of 12 months with 3-month intervals.
    [Show full text]
  • Aggravation by Paroxetine, a Selective Serotonin Re-Uptake Inhibitor, of Antral Lesions Generated by Nonsteroidal Anti-Inflammatory Drugs in Rats
    JPET Fast Forward. Published on June 24, 2011 as DOI: 10.1124/jpet.111.183293 JPET ThisFast article Forward. has not been Published copyedited andon formatted.June 24, The 2011 final versionas DOI:10.1124/jpet.111.183293 may differ from this version. JPET #183293 . Aggravation by Paroxetine, A Selective Serotonin Re-Uptake Inhibitor, of Antral Lesions Generated by Nonsteroidal Anti-inflammatory Drugs in Rats Downloaded from Koji Takeuchi, Akiko Tanaka, Kazuo Nukui, Azusa Kojo, Melinda Gyenge, and Kikuko Amagase jpet.aspetjournals.org at ASPET Journals on September 25, 2021 Division of Pathological Sciences Department of Pharmacology and Experimental Therapeutics Kyoto Pharmaceutical University Misasagi, Yamashina, Kyoto 607-8414, Japan (K.T., A.T., K.N., A.K., M.G., K.A.) 1 Copyright 2011 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on June 24, 2011 as DOI: 10.1124/jpet.111.183293 This article has not been copyedited and formatted. The final version may differ from this version. JPET #183293 . Short title: Aggravation by SSRIs of NSAID-Induced Antral Damage Address correspondence to: Dr. Koji Takeuchi Division of Pathological Sciences Department of Pharmacology and Experimental therapeutics Kyoto Pharmaceutical University Downloaded from Misasagi, Yamashina, Kyoto 607-8414, Japan Tel: (Japan) 075-595-4679; Fax: (Japan) 075-595-4774 E-mail: [email protected] jpet.aspetjournals.org Document statistics: text ------------------------ 21 pages (page 4~page 25) at ASPET Journals on September 25, 2021 figures ----------------------- 10 figures references ----------------------- 43 references (page 27~page 31) Number of words: abstract ----------------------- 247 introduction ----------------------- 410 discussion -----------------------1685 Recommended section: Gastrointestinal, Hepatic, Pulmonary, & Renal 2 JPET Fast Forward.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Evidence-Based Clinical Practice Guidelines for Peptic Ulcer Disease 2015
    J Gastroenterol DOI 10.1007/s00535-016-1166-4 SPECIAL ARTICLE Evidence-based clinical practice guidelines for peptic ulcer disease 2015 1,2 2 2 2 Kiichi Satoh • Junji Yoshino • Taiji Akamatsu • Toshiyuki Itoh • 2 2 2 2 Mototsugu Kato • Tomoari Kamada • Atsushi Takagi • Toshimi Chiba • 2 2 2 2 Sachiyo Nomura • Yuji Mizokami • Kazunari Murakami • Choitsu Sakamoto • 2 2 2 2 Hideyuki Hiraishi • Masao Ichinose • Naomi Uemura • Hidemi Goto • 2 2 2 2 Takashi Joh • Hiroto Miwa • Kentaro Sugano • Tooru Shimosegawa Received: 25 December 2015 / Accepted: 6 January 2016 Ó Japanese Society of Gastroenterology 2016 Abstract The Japanese Society of Gastroenterology bleeding is first treated by endoscopic hemostasis. If it (JSGE) revised the evidence-based clinical practice fails, surgery or interventional radiology is chosen. Second, guidelines for peptic ulcer disease in 2014 and has created medical therapy is provided. In cases of NSAID-related an English version. The revised guidelines consist of seven ulcers, use of NSAIDs is stopped, and anti-ulcer therapy is items: bleeding gastric and duodenal ulcers, Helicobacter provided. If NSAID use must continue, the ulcer is treated pylori (H. pylori) eradication therapy, non-eradication with a proton pump inhibitor (PPI) or prostaglandin analog. therapy, drug-induced ulcer, non-H. pylori, non-nons- In cases with no NSAID use, H. pylori-positive patients teroidal anti-inflammatory drug (NSAID) ulcer, surgical receive eradication and anti-ulcer therapy. If first-line treatment, and conservative therapy for perforation and eradication therapy fails, second-line therapy is given. In stenosis. Ninety clinical questions (CQs) were developed, cases of non-H.
    [Show full text]
  • Prevention of Gastric Ulcers
    24 Prevention of Gastric Ulcers Mohamed Morsy and Azza El-Sheikh Pharmacology Department, Minia University Egypt 1. Introduction Upper gastrointestinal tract integrity is dependent upon the delicate balance between naturally occurring protective factors as mucus or prostaglandins and damaging factors as hydrochloric acid present normally in the digestive juices. An imbalance causes peptic ulcer formation and destruction of gastrointestinal tract mucosal lining. Ulcer may develop in the esophagus, stomach, duodenum or other areas of elementary canal. In women, gastric ulcers are more common than duodenal ulcers, while in men the opposite is true. The ulcer irritates surrounding nerves and causes a considerable amount of pain. Obstruction of the gastrointestinal tract may occur as a result of spasm or edema in the affected area. The ulcer may also cause the erosion of major blood vessels leading to hemorrhage, hematemesis and/or melena. Deep erosion of the wall of the stomach or the intestine may cause perforation and peritonitis, which is a life-threatening condition needing emergency intervention. Duodenal ulcers are almost always benign but stomach ulcers may turn malignant. Although mortality rates of peptic ulcer are low, the high prevalence of the disease, the accompanying pain and its complications are very costly. The ongoing rapidly expanding research in this field provides evidence suggesting that, with therapeutic and dietetic advances, gastric ulcer may become preventable within the next decade. This could be achieved by strengthening the defense mechanisms of the gastric mucosa and, in parallel, limiting the aggression of predisposing factors causing gastric ulceration. The defenses of the gastric mucosa are incredibly efficient under normal mechanical, thermal or chemical conditions.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel Et Al
    USOO698.6901B2 (12) United States Patent (10) Patent No.: US 6,986,901 B2 Meisel et al. (45) Date of Patent: Jan. 17, 2006 (54) GASTROINTESTINAL COMPOSITIONS 6,121,301 A 9/2000 Nagasawa et al. 6,127,418 A 10/2000 Bueno et al. (75) Inventors: Gerard M. Meisel, Budd Lake, NJ 6,156,771. A 12/2000 Rubin et al. S. Arthur A. Ciociola, Far Hills, NJ FOREIGN PATENT DOCUMENTS CA 967977 5/1975 (73) Assignee: Warner-Lambert Company LLC, CA 2136164 3/1995 Morris Plains, NJ (US) CN 1092314 3/1993 CN 1118267 5/1994 (*) Notice: Subject to any disclaimer, the term of this DE 9859.499 : 12/1998 patent is extended or adjusted under 35 E. O S. A1 3.10: U.S.C. 154(b) by 234 days. FR 2244469 8/1973 FR 4506 8/1993 (21) Appl. No.: 10/196,053 FR 277 1009 11/1997 JP 56128719 3/1980 (22) Filed: Jul. 15, 2002 JP 306.6627 8/1989 O O JP 9052829 6/1995 (65) Prior Publication Data WO WO 95.01803 A1 * 1/1995 US 2004/0013741 A1 Jan. 22, 2004 WO WO 9725,979 1/1996 WO WOOO765OO 12/2000 (51) Int. Cl. WO WOO121601 3/2001 A6IF I3/00 (2006.01) ZA 61O1840 8/1993 A6F 99.6A06 3032006.O1 OTHER PUBLICATIONS A6 IK 948 (2006.01) JW Read, JL Abitbol, KD Bardhan, PJ Whorwell, B Fraitag-"Efficacy and Safety of the peripheral kappa ago (52) U.S. Cl. ....................... 424/436; 424/422; 424/430; nist fedotoZine verSuS placebo in the treatment of functional 424/433; 424/451; 424/464; 424/489 dyspepsia see comments)." Gut Nov., 1997 41(5):664-8.
    [Show full text]
  • Management of Duodenal Ulcer with Gastroesophageal Reflux Disease (GERD) with Intravenous Pantoprazole
    CASE REPORT Management of Duodenal Ulcer with Gastroesophageal Reflux Disease (GERD) with Intravenous Pantoprazole Ari Fahrial Syam, Murdani Abdullah, Marcellus Simadibrata, Dadang Makmun, Chudahman Manan, Daldiyono Hardjodisasto Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, University of Indonesia/Dr. Cipto Mangunkusumo General National Hospital ABSTRACT Proton pump inhibitors (PPIs) are the most effective anti secretory drugs available for controlling gastric acid acidity and volume. They are the drug of choice in the treatment for gastro esophageal reflux disease (GERD), Helicobacter pylori eradication, peptic ulcer and non steroidal anti-inflammatory drug (NSAID) gastropathy: For acute cases, an intravenous PPI is needed, especially for hospitalized patient. Recently, intravenous pantoprazole represents an alternative to intravenous histamine-2 receptor antagonists. We observed 2 patients who were treated with pantoprazole for duodenal ulcer, where one case had a complication of bleeding with a history of long term use of NSAID. After two weeks of treatment with pantoprazole, significant lesion healing from endoscopy findings was achieved in both cases. Keywords: peptic ulcer - upper gastrointestinal bleeding – proton pump inhibitors – pantoprazole INTRODUCTION Up to now, there has been no report on the use of Proton pump inhibitor (PPI) is currently the most pantoprazole in Indonesia. This paper reports two cases effective acid suppression, replacing histamine-2 of duodenal ulcer, where one case had a complication of bleeding with a history of long-term use of NSAID. The receptor antagonists (H2RA). At this time, this group of drugs has become the standard treatment for other case was that of duodenal ulcer in a patient with a gastroesophageal reflux disease (GERD), Helicobacter high dose of steroid.
    [Show full text]
  • Efficiency of the Inclusion of Rebamipide in The
    Journal of Clinical Medicine Article Efficiency of the Inclusion of Rebamipide in the Eradication Therapy for Helicobacter pylori Infection: Meta-Analysis of Randomized Controlled Studies Dmitrii N. Andreev * , Igor V. Maev and Diana T. Dicheva Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, 127473 Moscow, Russia; [email protected] (I.V.M.); [email protected] (D.T.D.) * Correspondence: [email protected]; Tel.: +7(495)6096700 Received: 14 August 2019; Accepted: 18 September 2019; Published: 19 September 2019 Abstract: Background: There has been a negative trend in the effectiveness of classic eradication therapy regimens for Helicobacter pylori (H. pylori), which has largely been determined from the emergence and spread of antibiotic resistance. Several studies have shown that adding rebamipide to eradication regimens leads to an increase in the effectiveness of treatment. Aim: To evaluate the efficacy and safety of including rebamipide in the eradication regimens for H. pylori infection. Methods: The literature search was conducted in the MEDLINE/PubMed, EMBASE, Cochrane Central Register, Korean Medical Citation Index, and Russian Science Citation Index databases. All identified randomized controlled trials comparing rebamipide supplementation with non-rebamipide-containing eradication regimens for the treatment of H. pylori infection were included in the final analysis. Results: We identified 11 randomized controlled trials (RCTs) involving 1227 patients (631 in groups with rebamipide and 596 in groups without rebamipide). The meta-analysis showed that the addition of rebamipide to eradication regimens significantly increased the effectiveness of treatment (odds ratio (OR) 1.753, 95% confidence interval (CI) 1.312–2.333, p < 0.001).
    [Show full text]
  • WO 2007/070082 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 21 June 2007 (21.06.2007) WO 2007/070082 Al (51) International Patent Classification: (74) Agent: YAO, Gene; 2600 Aramark Tower, 1101 Market A61K 9164 (2006.01) Street, Philadelphia, Pennsylvania 19107 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2006/0 18000 kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, (22) International Filing Date: IMay 2006 (09.05.2006) CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, (25) Filing Language: English KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY,MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, (26) Publication Language: English NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW (30) Priority Data: 60/679,424 10 May 2005 (10.05.2005) US (84) Designated States (unless otherwise indicated, for every 11/372,857 10 March 2006 (10.03.2006) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ELAN ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), PHARMA INTERNATIONAL LIMITED [IE/IE]; European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, Monksland, Athlone, County Westmeath (IE).
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • Functional Dyspepsia
    Erwin Budi Cahyono DEFINITION : Symptoms like pain or nausea in epigastrium accompanied by disgust, vomit, bloat, easy to full, fullness or nitre, which is suspected come from the abnormality of upper gastro- intestinal tractus. Dyspepsia: pathogenic mechanisms Dysmotility H. pylori infection/ Altered gastric inflammation acid secretion Mechanisms of dyspepsia Psychosocial Gut hypersensitivity factors Witteman & Tytgat, Netherlands J Med 1995; 46: 205–11. Talley et al., BMJ 2001; 323:1294–7. Tack et al., Curr Gastroenterol Rep 2001; 3: 503–8. Dyspepsia: symptom assessment Nature of symptoms Severity of Character symptoms Radiation Timing, duration and frequency Modifying factors Assessment of symptoms Patient’s degree Alarm features of distress Paré, Can J Gastroenterol 1999; 13: 647–54. acute dyspepsia (new onset dyspepsia) Suddenly Sigh with the quality of sigh which is usually more tremendous with a longer response to the medication. chronic dyspepsia Sigh which is sometimes disappear, sometimes appear, more than two weeks. The sigh is not as tremendous as acute dyspepsia with a quick response to the medication. Organic Dyspepsia : There is an organ abnormality as ulcer gastro- duodenal, gastro esofageal reflux and gastric carcinoma (Talley, 1998) A common term which is given to the patient as : abdominal pain or nausea on the upper of stomach which is repeatedly happen more than three months, and at least a long of that time 25% symptoms of dyspepsia appear and no evidence organic disease which is responsible to that symptoms
    [Show full text]